SCYNEXIS (FRA:135) Ending Cash Position: €9.27 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:135 SCYNEXIS Inc FRA:135
40 GF Score
Price €4.36
GF Value €14.60
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Ending Cash Position?

SCYNEXIS FRA:135 +1.40% 40 Ending Cash Position is €9.27 Mil as of Jun. 2026. GuruFocus rates FRA:135 with a GF Score™ of 40/100 and a GF Value™ of €14.60. The stock has 3 warning signs investors should review.

SCYNEXIS's Ending Cash Position for the quarter that ended in Jun. 2026 was €9.27 Mil.

SCYNEXIS's quarterly Ending Cash Position increased from Dec. 2025 (€18.32 Mil) to Mar. 2026 (€31.88 Mil) but then declined from Mar. 2026 (€31.88 Mil) to Jun. 2026 (€9.27 Mil).

SCYNEXIS's annual Ending Cash Position declined from Dec. 2023 (€31.72 Mil) to Dec. 2024 (€15.85 Mil) but then increased from Dec. 2024 (€15.85 Mil) to Dec. 2025 (€18.32 Mil).

SCYNEXIS Ending Cash Position Related Terms

SCYNEXIS Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Ending Cash Position Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.66 43.45 31.72 15.85 18.32

SCYNEXIS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.77 12.77 18.32 31.88 9.27
FRA:135
40GF Score
SCYNEXIS Inc FRA:135
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SCYNEXIS's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=14.173+4.144
=18.32

SCYNEXIS's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=31.995+-22.728
=9.27

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €9.27 Mil mean?
SCYNEXIS (FRA:135) has a Ending Cash Position of €9.27 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Ending Cash Position too high?
SCYNEXIS's current Ending Cash Position is €9.27 Mil. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Ending Cash Position compare to IXHL and ETST?
SCYNEXIS's Ending Cash Position of €9.27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Ending Cash Position is €9.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Ending Cash Position of €9.27 Mil. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Ending Cash Position is €9.27 Mil. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Ending Cash Position is €9.27 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (FRA:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.

Key valuation signals for FRA:135:

  • Ending Cash Position: €9.27 Mil
  • GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for FRA:135

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.36
Price
€14.60
GF Value